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MicroRNAs (miRNAs) are a class of short non-coding RNA, which interact with the 3’ UTR region 
of complementary mRNA to decrease or inhibit the translation of proteins (Lai, 2002). MiRNAs 
regulate pathways in various pathophysiological status, and are regarded as biomarkers for 
early diagnosis of several diseases, including cancer (Di Leva et al., 2014). 
The study aims to evaluate the quality and purity of miRNAs extracted from a) 11 archival 
Formalin Fixed and Paraffin Embedded (FFPE) samples of Mast Cell Tumour (MCT) at stage I, II, 
III and IV, and 8 intra-patient healthy controls; b) samples collected during surgery, including 6 
samples of saliva, primary tumour biopsy and serum/plasma. The quality of miRNA largely 
influence the downstream experiments, and must be carefully evaluated before performing for 
examples, the sequencing reaction. MiRNA extraction was carried out using commercial kits 
(Qiagen) and quantify using Small RNA Kit (Agilent) on Agilent 2100 Bioanalyzer (Figure 1). The 
results showed that the concentration of miRNAs from FFPE, saliva,  primary tumor biopsy and 
serum was acceptable with a Median (Me)= 56,91 ng/µl, Me=10,30 ng/µl, Me=3,44 ng/µl and  
Me=0,71 ng/µl, and a miRNA/Small RNA ratio of 48%, 61%, 17% and 76%, respectively. The 
concentration of miRNAs from plasma was not detectable. Studies reveal that plasma ranks as 
the first choice source for diagnostic purpose, much more than serum (Aung et al., 2014), but 
the debate remains open and subsequent analyses are needed. 
The concentration of miRNAs from FFPE and saliva samples is higher than that from other 
matrices. Possible explanations include a) different quantity and quality of starting materials; b) 
nucleic acids fragmentation, due to the formalin fixation and paraffin embedded procedure; c) 
presence of nucleases in saliva, which produce small fragments recognized as miRNAs or 
smallRNAs. 
In conclusion, the quantity and the purity of miRNAs, obtained using Qiagen commercial kits, 
are reliable for further NGS analysis.  
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Figure 1:  Example of electropherogram of a serum sample obtained from Agilent 2100 Bioanalyzer. It shows 
the number of nucleotides (X axis) and the fluorescence signal (Y axis). The higher peak on the left 
corresponding to the marker, instead the others peaks represent the miRNA (10-40 nucleotides region) and 
Small RNA (0-150 nucleotides region) present into the sample. 
